Criticism has been expressed from time to time that United States pharmaceutical companies present different prescribing information to physicians in developing countries from that approved and published in the United States. This article discusses some of the factors which may lead to different statements in national labels. It also provides an outlook on trends toward harmonization in the European Union.
DunlopDJ. The State of British Medicine, 5. The innovation, benefits, drawbacks and control of drugs. J Roy Soc Med.1978;71:324–330.
2.
SilvermanM. Prescriptions for death: The drugging of the third world.Berkeley, CA: University of California Press; 1982.
3.
BerglundGAnderssonO. Low doses of hydrochlorothiazide in hypertension, Antihypertensive and metabolic effects. Eur J Clin Pharmacol.1976;10:177–182.
4.
BeermanBGroschinsky-GrindM. Antihypertensive effect of various doses of hydrochlorothiazide and its relation to the plasma level of the drug. Eur J Clin Pharmacol.1978;13:195–201.
5.
Physicians' Desk Reference.49th Edition. Montvale, NJ: Medical Economics; 1995.
